RT Journal Article
SR Electronic
T1 Application of hybrid failure mode effect analysis based on fuzzy AHP and fuzzy TOPSIS in quality risk assessment of fixed-dose artemether-lumefantrine tablets
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.26.24301832
DO 10.1101/2024.01.26.24301832
A1 Ilyasu, Salim
A1 Malami, Sani
A1 Khalid, Garba Mohammed
A1 Abdussalam, Umar Sharif
A1 Dawud, Abubakar Magaji
A1 Mohammed, Saratu
A1 Falalu, Al-Kasim Rabiu
A1 Zaharadeen, Mustapha Fatima
A1 Sani, Farouq Idris
A1 Manu, Abdussalam Yayo
A1 Yakasai, Ibrahim Adamu
A1 Chedi, Basheer Abba-Zubair
A1 Bello, Aminu Sahalu
A1 Ibrahim, Adam Bashir
A1 Julde, Saadatu
A1 Idris, Maryam Shehu
A1 Bichi, Lawal Alhassan
YR 2024
UL http://medrxiv.org/content/early/2024/01/28/2024.01.26.24301832.abstract
AB Background A hybrid Failure Mode Effect Analysis (FMEA) based on fuzzy logic and multicriteria decision analytics was applied as a post-marketing surveillance tool for troubleshooting potential quality problems of Artemisinin Combination Therapies (ACTs) as a means of aggregating subjective opinions of quality experts in providing vital information for continuous management and improvement of safety and quality standards.Research design and methods An FMEA team of five cross-functional quality experts implemented a hybrid fuzzy FMEA model based on Analytical Hierarchy Process (AHP) and Technique for Order of Preference by Similarity to Ideal Solution (TOPSIS) to solve multicriteria decision problems in quality risk analysis of historic quality control data of ACTs.Results Expert opinions were captured as triangular fuzzy numbers to represent the linguistic scoring of risk-determining variables for fifteen failure modes. The fuzzy AHP enabled systematic ranking of the variables, while the fuzzy TOPSIS algorithm provided easily understood and configurable computational procedures for ranking the failure modes based on optimal geometric paths to positive and negative ideal solutions.Conclusions The quality risk of ACTs could be reliably established using the fuzzy FMEA where aggregated experts’ decisions and risk variables’ weights are of considerable importance to the final ranking of quality failures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Research Fund of the Tertiary Education Trust Fund Grant Number TETF/DR&D/CE/NRF/CC/20/VOL 1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical approval for the conduct of the study was granted by the College Research Ethics Committee of the College of Health Sciences, Bayero University (Reference number: BUK/CHS-REC/121).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online via the link: https://data.mendeley.com/preview/hg7z83brcv?a=d8f53913-d5a9-4a49-8964-.https://data.mendeley.com/preview/hg7z83brcv?a=d8f53913-d5a9-4a49-8964-